Abstract: | Improving the value of outcomes from research and development is always high on the agenda of senior executives in the pharmaceutical industry, but there are many problems to address before productivity can be increased. The rate of discovering and developing new products is often not fast enough to hit financial targets. Regulatory agencies continually demand more assurance, more data - and more expenditure. |